右美托咪定在胸外科手术患者中的应用

目的：实践性研究右美托咪定运用于胸外科手术患者的安全性以及有效性。方法右美托咪定给药方法为，在患者麻醉诱导之前、在诱导时与诱导后（8±1.7）min之内输注1μg/kg。细致的观察两组麻醉效果、麻醉维持期丙泊酚TCI的靶饱和度以及麻醉恢复室里用药情况与副作用等。结果通过分析发现右美组在麻醉维持阶段丙泊酚TCI的靶饱和度每毫升少于（2.37±0.4）μg的病例数显著的超过非右美组，差异有统计学意义（P〈0.01）。麻醉恢复室里右美组予以曲马多的病例数显著少于非右美组。右美组在诱导时以及诱导后用药一过性血压提升率少于麻醉诱导前用药，差异有统计学意义（P〈0.01）。右美组心动过缓的出现率少于（4.1±0.3）%。结论予以右美托咪定的有效性在于能够减少麻醉维持阶段丙泊酚TCI的靶饱和度，减少苏醒阶段其他药物的使用率。

Application of dexmedetomidine in thoracic surgery

Objective To study safety and effectiveness of dexmedetomidine in thoracic surgery. Methods Dexmedetomidine administration methods was that before induction of anesthesia, at the time of induction and post induction （8±1.7） minutes giving patients infusion of 1 μg/kg, carefully observed anesthesia effect of two groups, propofol TCI saturation in anesthesia maintenance phase and the recovery room medication and side effects of anesthesia. Results Propofol TCI saturation in anesthesia maintenance phase of dexmedetomidine group was less than （2.37 ± 0.4）μg/ml, which was significantly more than nondexmedetomidine group, P〈0.01. Anesthesia recovery room dexmedetomidine group to display case of tramadol with less than nondexmedetomidine group. Dextromethorphan group in the induction and inducing drugs after a blood pressure increase rate less than before the induction of anesthesia medication, P〈0.01. Dextromethorphan group heartbeat bradycardia occurrence rate of less than （4.1±0.3）%. Conclusion Dexmedetomidine can reduce the propofol TCI saturation in anesthesia maintenance phase and use rate of other drugs in recovery stage.